NEW YORK (GenomeWeb News) — Cogenics and Epigenomics have signed a co-marketing agreement for DNA methylation, Cogenics’ parent company Clinical Data said today.
Under the deal, Cogenics will promote Epigenomics' services for genome-wide DNA methylation analysis, bisulfite sequencing, and PCR, which are performed in Epigenomics’ facilities in Germany.
Also under the deal, the companies will offer regulated DNA methylation analyses in Cogenics’ US labs. Epigenomics will promote these services through its Clinical Solutions segment.
Robert Bondaryk, senior vice president and general manager of Cogenics, said the pact expands the company’s biomarker offerings to include DNA methylation for disease diagnosis, prognosis, and drug response prediction.
Christina Dahlstroem, Clinical Solutions’ senior vice president, said the agreement will be “particularly important” to her company when pharmaceutical customers begin to use these biomarkers in clinical trials.